ArticleResearch and reports in urology2017
Rationale of combination therapy with antioxidants in medical management of Peyronie's disease: results of clinical application.
Article in Research and reports in urology, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
10 citing papers in PubMed, 1 synthesis or guideline pooled it, 15 citations in OpenAlex.
- Updated recommendations on the therapeutic role of extracorporeal shock wave therapy for peyronie's disease: systematic review and meta-analysis.BMC urology · 2023Pooled it
- Oxidative Mechanism of Peyronie's Disease and Effectiveness of Pentoxifylline in the Therapeutic Management: A Narrative Review.Antioxidants (Basel, Switzerland) · 2025Review
- Peyronie's Disease: An Outcomes-Based Guide to Non-Surgical and Novel Treatment Modalities.Research and reports in urology · 2023Review
- Role of Oxidative Stress in Peyronie's Disease: Biochemical Evidence and Experiences of Treatment with Antioxidants.International journal of molecular sciences · 2022Review
- Trends in treatment of Peyronie's disease in adult men in the United States from 2008 to 2017-results from an encounter and claims database.International journal of impotence research · 2022Article
- Conservative Therapy for Peyronie's Disease: a Contemporary Review of the Literature.Current urology reports · 2021Review
- Recent advances in managing Peyronie's disease.F1000Research · 2020Review
- Antioxidant Mechanism of Xiaojin Pill () for Treatment of Peyronie's Disease in Rats Based on Matrix Metalloproteinases.Chinese journal of integrative medicine · 2019Article
- Could coenzyme Q10 be the treatment for Dupuytren's disease?BMJ case reports · 2019Article
- Superoxide dismutase: Challenges, opportunities, and promises for clinical translation.International journal of health sciencesArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Peyronie's disease (PD) is a connective tissue disorder involving the tunica albuginea of the corpora cavernosa of the penis. We have published several studies describing a "combined therapy" for PD patients, but the present study aims to clearly demonstrate how the association between various antioxidants in PD treatment can significantly increase the likelihood of therapeutic success. We used the following substances: silymarin,
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.